ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigations Regarding B-cell Subsets in Humans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00926692
Recruitment Status : Completed
First Posted : June 23, 2009
Last Update Posted : August 26, 2015
Sponsor:
Information provided by (Responsible Party):
Daniel Griffin, Northwell Health

Brief Summary:
The aim of this research is to define the human equivalent of mouse B1 cells.

Condition or disease Intervention/treatment
Healthy Other: Blood draw

Detailed Description:

The specific aim of this research project is to define the human equivalent of mouse B1 cells. This will be done by evaluating IgM secretion, surface markers, functional characteristics, V gene usage, N-region addition, and phosphorylation status of intracellular proteins, gene expression, sequencing of immunoglobulin genes, determination of antigenic specificity, replication history, and response to different stimuli.

The goal of this project is to begin to the translation of decades of basic science research and research in the mouse model into the human system. It is believed that properly defining this B cell subset in humans will lead to better therapeutics, prognostics and prevention for a number of disease including infections, autoimmune disease, and cancer.


Study Type : Observational
Actual Enrollment : 249 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Investigations Regarding B-cell Subsets in Humans
Study Start Date : April 2009
Actual Primary Completion Date : July 2014
Actual Study Completion Date : July 2014

Group/Cohort Intervention/treatment
Healthy Subjects
All subjects are considered healthy
Other: Blood draw
Subject will have blood draw.



Primary Outcome Measures :
  1. Presence of B-1 cells in humans [ Time Frame: determined over the years study in effect ]
    an equivalent cell type was isolated in humans



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy Control Population
Criteria

Inclusion Criteria:

  • Subject is considered by the physician to be a healthy adult.

Exclusion Criteria:

  • Subject is under the age of 18
  • Subject has an infection or is currently ill

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00926692


Locations
United States, New York
Feinstein Institute for Medical Research
Manhasset, New York, United States, 11030
Sponsors and Collaborators
Northwell Health
Investigators
Principal Investigator: Daniel Griffin, M.D. Feinstein Institute for Medical Research

Responsible Party: Daniel Griffin, Fellow Infectious Diseases, Northwell Health
ClinicalTrials.gov Identifier: NCT00926692     History of Changes
Other Study ID Numbers: GCRC 0266
First Posted: June 23, 2009    Key Record Dates
Last Update Posted: August 26, 2015
Last Verified: August 2015

Keywords provided by Daniel Griffin, Northwell Health:
B-cells
CD5+
B1 Cells
Healthy Controls